Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 4, 2014, Pages 1005-1016

  Antoine, Thomas ^a   Fisher, Nicholas ^a   Amewu, Richard ^b   O'Neill, Paul M ^b   Ward, Stephen A ^a   Biagini, Giancarlo A ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Free radicals; Haem; Iron; Lipid peroxidation; Mitochondria; Oxidative damage; Plasmodium

Indexed keywords

ARTEMETHER; ARTEMISININ; ARTESUNATE; ATOVAQUONE; CYANIDE; CYTOCHROME C OXIDASE; DEFEROXAMINE; DIHYDROARTEMISININ; ENDOPEROXIDE; FREE RADICAL; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE; TETRAOXANE DERIVATIVE; TIRON;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVITY; HETEROLOGOUS EXPRESSION; IC 50; LIPID PEROXIDATION; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PLASMODIUM; RESPIRATORY CHAIN;

FREE RADICALS; HAEM; IRON; LIPID PEROXIDATION; MITOCHONDRIA; OXIDATIVE DAMAGE; PLASMODIUM;

ARTEMISININS; CELL MEMBRANE; CELL SURVIVAL; ELECTRON TRANSPORT; IRON; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; OXIDATIVE STRESS; PEROXIDASES; PLASMODIUM FALCIPARUM; REACTIVE OXYGEN SPECIES;

EID: 84896485226     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt486     Document Type: Article

References (73)

1. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049-55.
2. Charman SA, Arbe-Barnes S, Bathurst IC et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 2011; 108: 4400-5.
3. O'Neill PM, Amewu RK, Nixon GL et al. Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew Chem Int Ed Engl 2010; 49: 5693-7.
4. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin-the debate continues. Molecules 2010; 15: 1705-21.
5. Meshnick SR, Yang YZ, Lima V et al. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 1993; 37: 1108-14.
6. Meshnick SR, Thomas A, Ranz A et al. Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 1991; 49: 181-9.
7. Posner GH, Oh CH, Wang D et al. Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: the importance of a carbon-centered radical for antimalarial activity. J Med Chem 1994; 37: 1256-8.
8. Posner GH, Wang D, Cumming JN et al. Further evidence supporting the importance of and the restrictions on a carbon-centered radical for high antimalarial activity of 1,2,4-trioxanes like artemisinin. J Med Chem 1995; 38: 2273-5.
9. Butler AR, Gilbert BC, Hulme P et al. EPR evidence for the involvement of free radicals in the iron-catalysed decomposition of qinghaosu (artemisinin) and some derivatives; antimalarial action of some polycyclic endoperoxides. Free Radic Res 1998; 28: 471-6.
10. O'Neill PM, Bishop LP, Searle NL et al. Biomimetic Fe(II)-mediated degradation of arteflene (Ro-42-1611). The first EPR spin-trapping evidence for the previously postulated secondary carbon-centered cyclohexyl radical. J Org Chem 2000; 65: 1578-82.
11. Wu W-M, Wu Y, Wu Y-L et al. Unified mechanistic framework for the Fe(II)-induced cleavage of qinghaosu and derivatives/analogues. The first spin-trapping evidence for the previously postulated secondary C-4 radical. J AmChem Soc 1998; 120: 3316-25.
12. Robert A, Benoit-Vical F, Claparols C et al. The antimalarial drug artemisinin alkylates heme in infected mice. Proc Natl Acad Sci USA 2005; 102: 13676-80.
13. Wu Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc Chem Res 2002; 35: 255-9.
14. 2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. ChemMedChem 2007; 2: 1480-97.
15. Haynes RK, Pai HH-O,Voerste A. Ring opening of artemisinin (qinghaosu) and dihydroartemisinin and interception of the open hydroperoxides with formation of N-oxides-a chemical model for antimalarial mode of action. Tetrahedron Lett 1999; 40: 4715-8.
16. Li W, Mo W, Shen D et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genetics 2005; 1: e36.
17. Wang J, Huang L, Li J et al. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010; 5: e9582.
18. Haynes RK, Cheu KW, Chan HW et al. Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model-a unifying proposal for drug action. Chem Med Chem 2012; 7: 2204-26.
19. Olliaro P. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol Ther 2001; 89: 207-19.
20. Golenser J, Waknine JH, Krugliak M et al. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 2006; 36: 1427-41.
21. Maeno Y, Toyoshima T, Fujioka H et al. Morphologic effects of artemisinin in Plasmodium falciparum. Am J Trop Med Hyg 1993; 49: 485-91.
22. Klonis N, Crespo-Ortiz MP, Bottova I et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA 2011; 108: 11405-10.
23. Berman PA, Adams PA. Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Rad Biol Med 1997; 22: 1283-8.
24. Pandey AV, Tekwani BL, Singh RL et al. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems inmalarial parasite. J Biol Chem1999; 274: 19383-8.
25. Kannan R, Sahal D, Chauhan VS. Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibithemepolymerization.Chem Biol 2002; 9: 321-32.
26. Zhang S, Gerhard GS. Heme activates artemisinin more efficiently than hemin, inorganic iron, or hemoglobin. BioorgMedChem 2008;16: 7853-61.
27. Hartwig CL, Rosenthal AS, D'Angelo J et al. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites isendoperoxide-dependent. BiochemPharmacol 2009;77:322-36.
28. Pisciotta JM, Coppens I, Tripathi AK et al. The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J 2007; 402: 197-204.
29. Ellis DS, Li ZL, Gu HM et al. The chemotherapy of rodent malaria, XXXIX. Ultrastructural changes following treatment with artemisinine of Plasmodium berghei infection in mice, with observations of the localization of [3H]-dihydroartemisinine in P. falciparum in vitro. Ann Trop Med Parasitol 1985; 79: 367-74.
30. Eckstein-Ludwig U, Webb RJ, Van Goethem ID et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424: 957-61.
31. Haynes RK, Ho WY, Chan HW et al. Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew Chem Int Ed Engl 2004; 43: 1381-5.
32. Haynes RK, Monti D, Taramelli D et al. Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrob Agents Chemother 2003; 47: 1175.
33. Pradines B, Rolain JM, Ramiandrasoa F et al. Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum. J Antimicrob Chemother 2002; 50: 177-87.
34. Bhisutthibhan J, Pan XQ, Hossler PA et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem 1998; 273: 16192-8.
35. Jiang JB, Jacobs G, Liang DS et al. Qinghaosu-induced changes in the morphology of Plasmodium inui. Am J Trop Med Hyg 1985; 34: 424-8.
36. Kawai S, Kano S, Suzuki M. Morphologic effects of artemether on Plasmodium falciparum in Aotus trivirgatus. Am J Trop Med Hyg 1993; 49: 812-8.
37. Zhao Y, Hanton WK, Lee KH. Antimalarial agents, 2. Artesunate, an inhibitor of cytochrome oxidase activity in Plasmodium berghei. J Nat Prod 1986; 49: 139-42.
38. Krungkrai J, Burat D, Kudan S et al. Mitochondrialoxygenconsumption in asexual and sexual blood stages of the human malarial parasite, Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1999; 30: 636-42.
39. Fisher N, Bray PG, Ward SA et al. The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends Parasitol 2007; 23: 305-10.
40. Fisher N, Warman A, Ward SA et al. Type IINADH:quinoneoxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis: kinetic and high-throughput assays. Methods Enzymol 2009; 456: 303-20.
41. del Pilar Crespo M, Avery TD, Hanssen E et al. Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob Agents Chemother 2008; 52: 98-109.
42. Mercer AE, Copple IM, Maggs JL et al. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 2011; 286: 987-96.
43. Biagini GA, Viriyavejakul P, O'Neill PM et al. Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria. Antimicrob Agents Chemother 2006; 50: 1841-51.
44. Biagini GA, Fisher N, Berry N et al. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol Pharmacol 2008; 73: 1347-55.
45. Fisher N, Majid RA, Antoine T et al. Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J Biol Chem 2012; 287: 9731-41.
46. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193: 673-5.
47. Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 1979; 65: 418-20.
48. Smilkstein M, Sriwilaijaroen N, Kelly JX et al. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 2004; 48: 1803-6.
49. Fisher N, Castleden CK, Bourges I et al. Human disease-relatedmutations in cytochrome b studied in yeast. J Biol Chem2004; 279: 12951-8.
50. Lenaz G, Fato R, Baracca A et al. Mitochondrial quinone reductases: complex I. Methods Enzymol 2004; 382: 3-20.
51. Allen RJ, Kirk K.Themembranepotential of the intraerythrocytic malaria parasite Plasmodium falciparum. J Biol Chem 2004; 279: 11264-72.
52. Stocks PA, Bray PG, Barton VE et al. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew Chem Int Ed Engl 2007; 46: 6278-83.
53. Lloyd D, Hayes AJ. Vigor, vitality and viability of microorganisms. FEMS Microbiol Lett 1995; 133: 1-7.
54. Izumo A, Tanabe K, Kato M. The plasma membrane and mitochondrial membrane potentials of Plasmodiumyoelii. CompBiochemPhysiol B 1988; 91: 735-9.
55. +-ATPase localized in plasma membranes of malaria parasite cells, Plasmodium falciparum, is involved in regional acidification of parasitized erythrocytes. J Biol Chem 2000; 275: 34353-8.
56. +-ATPase. J Biol Chem 1999; 274: 33213-9.
57. van Schalkwyk DA, Chan XW, Misiano P et al. Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death. Biochem Pharmacol 2010; 79: 1291-9.
58. Lehane AM, Saliba KJ, Allen RJ et al. Choline uptake into the malaria parasite is energized by the membrane potential. Biochem Biophys Res Commun 2004; 320: 311-7.
59. Biagini GA, Pasini EM, Hughes R et al. Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs. Blood 2004; 104: 3372-7.
60. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 1997; 272: 3961-6.
61. Hammond DJ, Burchell JR, Pudney M. Inhibition of pyrimidine biosynthesis de novo in Plasmodiumfalciparumby 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol 1985; 14: 97-109.
62. Painter HJ, Morrisey JM, MatherMWet al. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 2007; 446: 88-91.
63. Sanz LM, Crespo B, De-Cozar C et al. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One 2012; 7: e30949.
64. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 1413-22.
65. Pukrittayakamee S, Chantra A, Simpson JA et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44: 1680-5.
66. Klonis N, Xie SC, McCaw JM et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci USA 2013; 110: 5157-62.
67. Makanga M, Bray PG, Horrocks P et al. Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria. Proteomics 2005; 5: 1849-58.
68. Brossi A, Venugopalan B, Dominguez Gerpe L et al. Arteether, a new antimalarial drug: synthesis and antimalarial properties. J Med Chem 1988; 31: 645-50.
69. Kaiser M, Wittlin S, Nehrbass-Stuedli A et al. Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrob Agents Chemother 2007; 51: 2991-3.
70. Hong YL, Yang YZ, Meshnick SR. The interaction of artemisinin with malarial hemozoin. Mol Biochem Parasitol 1994; 63: 121-8.
71. Schwarzenbach G, Anderegg G. [Metal complexes with biguanide]. Pharmaceutica Acta Helvetiae 1963; 38: 547-52.
72. Morel I, Cillard J, Lescoat G et al. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic Biol Med 1992; 13: 499-508.
73. van Schalkwyk DA, Saliba KJ, Biagini GA et al. Loss of pH control in Plasmodium falciparum parasites subjected to oxidative stress. PLoS One 2013; 8: e58933.